Skip to main content
. 2013 Nov 22;15(11):e257. doi: 10.2196/jmir.2662

Table 3.

Secondary outcome measures: improvements and differences between groupsa.

Outcome measures n Intervention, mean (95% CI) n Control, mean (95% CI) Difference, I-Cb(95% CI) ES P value
 
Sedentary intensity (accelerometer min/day)

Baseline 39 571 (498-645) 40 555 (479-630)

3 months 27 508 (454-563) 30 540 (477-603) −32 (−67.7 to 3.7) −0.20 .08

12 months 24 514 (448-580) 28 531 (467-595) −17 (−54.7 to 20.7) −0.10 .38
Pain (0-10)

Baseline 100 5.4 (4.2-6.5) 98 4.9 (3.7-6.1)



3 months 85 3.5 (2.5-4.6) 81 4.5 (3.4-5.7) −1 (−1.6 to −0.38) −0.20 .002

12 months 76 3.5 (2.4-4.5) 71 3.8 (2.7-4.9) −0.36 (−1.1 to 0.38) −0.07 .33
Tiredness (0-10)

Baseline 100 5.6 (4.3-6.9) 99 5.5 (4.3-6.8)

3 months 85 3.2 (2-4.4) 81 4.1 (2.9-5.3) −0.84 (−1.6 to -0.06) −0.16 .04

12 months 76 3 (1.9-4.2) 71 4.1 (3-5.2) −1.15 (−1.9 to −0.28) −0.22 .008
Symptoms (0-100)

Baseline 100 68.2 (60.2-76.2) 99 70.9 (62.7-79.2)

3 months 85 67.4 (59.1-75.8) 80 64.3 (55.3-73.2) 3.1 (−1.3 to 7.6) 0.08 .16

12 months 76 65.7 (57.4-74.0) 71 62.8 (53.4-72.1) 3 (−2.1 to 8.1) 0.08 .25
Quality of life (0-100)

Baseline 100 38 (30.6-45.5) 98 40.9 (33.6-48.2)

3 months 85 49.4 (41.7-57.0) 80 47.3 (39.4-55.1) 2.1 (−1.7 to 5.9) 0.06 .28

12 months 75 48.7 (40.8-56.6) 71 47.5 (39.3-55.6) 1.2 (−4.4 to 6.8) 0.03 .68
Sport/recreation (0-100)

Baseline 88 27.6 (14.7-40.4) 78 27.6 (13.4-41.9)

3 months 58 42.6 (29.6-55.6) 55 42.6 (29-56.2) 0 (−8.0 to 8.1) 0 1

12 months 53 42.4 (28.1-56.8) 47 39.6 (25.6-53.5) 2.9 (−6.3 to 12.1) 0.08 .54
Self-efficacy pain (1-5)

Baseline 100 4.1 (3.6-4.6) 97 3.8 (3.6-4.2)

3 months 85 4 (3.6-4.4) 79 3.7 (3.3-4.1) 0.31 (0.1-0.5) 0.17 .008

12 months 75 4 (3.6-4.4) 72 3.9 (3.5-4.3) 0.12 (−01 to 0.4) 0.06 .35
Self-efficacy other symptoms (1-5)

Baseline 100 3.6 (3.1-4.1) 96 3.8 (3.4-4.3)

3 months 85 4 (3.7-4.4) 79 3.8 (3.7-4.4) 0.21 (0-0.4) 0.12 .07

12 months 75 4.1 (3.7-4.4) 72 3.8 (3.5-4.2) 0.23 (0-0.5) 0.20 .05
Active pain coping (0-4)

Baseline 100 2.2 (2.0-2.4) 96 2.2 (2-2.4)

3 months 83 2 (1.9-2.2) 77 2 (1.8-2.2) −0.02 (−0.1 to 0.1) −0.02 .81

12 months 73 2 (1.8-2.2) 70 2 (1.8-2.2) 0 (−0.1 to 0.1) 0 .98
Passive pain coping (0-4)

Baseline 100 1.8 (1.7-2.0) 96 1.8 (1.6-1.9)

3 months 83 1.7 (1.6-1.8) 77 1.7 (1.6-1.9) −0.04 (−0.1 to 0.04) 0 .29

12 months 73 1.7 (1.5-1.8) 70 1.8 (1.7-1.9) −0.12 (−0.2 to –0.03) −0.18 .008
Internal locus of control (6-36)

Baseline 100 27.1 (25.1-29.2) 96 27.5 (25.2-29.8)

3 months 84 23.9 (21.9-25.8) 79 23.4 (21.3-25.6) 0.45 (−0.6 to 1.5) 0.06 .41

12 months 74 23.6 (21.7-25.6) 70 24 (21.7-26.2) −0.3 (−1.5 to 0.9) −0.05 .61
Powerful others locus of control (6-36)

Baseline 99 17.4 (14.8-20.0) 96 18.8 (15.8-21.8)

3 months 83 16.5 (15.0-18.0) 79 16.1 (14.3-18.0) 0.37 (−0.8 to 1.5) 0.05 .53

12 months 73 15.2 (13.6-6.9) 70 16 (14.1-17.9) −0.74 (−2.0 to 0.6) −0.1 .26
Anxiety (0-21)

Baseline 100 4 (2.5-5.6) 97 4.2 (2.6-5.9)

3 months 85 3.5 (2.5-4.5) 79 4.2 (3.1-5.2) −0.64 (−1.3 to 0) −0.15 .05

12 months 75 3.1 (2.0-4.3) 72 4.1 (2.9-5.2) −0.9 (−1.6 to −0.2) −0.21 .007
Depression (0-21)

Baseline 100 4 (2.5-5.6) 96 4.2 (2.6-5.9)

3 months 85 2.6 (1.5-3.7) 78 3.2 (2.1-4.3) −0.61 (−1.3 to 0.1) −0.12 .09

12 months 75 2.4 (1.3-3.6) 72 3 (1.9-4.2) −0.6 (−1.3 to 0.1) −0.12 .09

aFor symptoms, quality of life, sport and recreation, self-efficacy, active pain coping, and locus of control, a higher score indicates an improvement. For sedentary behavior, tiredness, pain, passive pain coping, anxiety and depression a lower score indicates an improvement. Results are based on GEE analyses and adjusted for corresponding baseline variables, age, OA location, and gender.

bI-C: difference between intervention and control group.